Lysofunction Platform / TRPML1
Neurodegenerative Diseases (ALS, PD, etc.)
PreclinicalActive
Key Facts
Indication
Neurodegenerative Diseases (ALS, PD, etc.)
Phase
Preclinical
Status
Active
Company
About Libra Therapeutics
Libra Therapeutics is a private, preclinical-stage biotech targeting neurodegenerative diseases through the modulation of lysosomal function and autophagy. Its core strategy involves a proprietary Lysofunction screening platform to identify compounds that enhance these cellular clearance pathways, with programs focused on TRPML1 activation and targeting the C9orf72 genetic mutation. The company is led by a team with deep neuroscience and drug development experience and is backed by a syndicate of life science venture capital firms.
View full company profile